Table 1.
Baseline characterization of patients.
| Female | Male | Missing * | Total | |
|---|---|---|---|---|
| Number of patients | 180 | 290 | 1 (sex) | 471 |
| Number of tumors | 183 | 296 | 1 (sex) | 480 |
| Tumors with available AR RPPA data | 144 | 208 | 1 (sex) | 353 |
| Tumors with available AR mRNA data | 180 | 289 | 1 (mRNA) | 471 |
| Number of primary tumors | 45 | 64 | 0 | 109 |
| Number of metastatic tumors | 138 | 232 | 1 (sex) | 371 |
| Age at diagnosis (years) | 58.5 ± 1.2 | 58.0 ± 0.9 | 9 (age) | 58.2 ± 0.7 |
| Stage of disease | ||||
| stage 0 | 2 | 5 | 7 | |
| stage 1 | 25 | 52 | 77 | |
| stage 2 | 61 | 93 | 154 | |
| stage 3 | 67 | 104 | 171 | |
| stage 4 | 8 | 15 | 23 | |
| missing | 17 | 21 | 1 (sex) | 39 |
| total | 180 | 290 | 471 | |
| Stage of disease ** | ||||
| early | 88 | 150 | 238 | |
| late | 75 | 119 | 194 | |
| missing | 17 | 21 | 1 (sex) | 39 |
| Ulceration | ||||
| no | 57 | 89 | 146 | |
| yes | 67 | 100 | 167 | |
| missing | 56 | 101 | 158 | |
| Breslow depth | ||||
| <1.0 mm | 20 | 36 | 56 | |
| 1.0–2.0 mm | 27 | 53 | 80 | |
| 2.0–4.0 mm | 33 | 44 | 77 | |
| >4.0 mm | 60 | 83 | 143 | |
| missing | 40 | 74 | 1 (sex) | 115 |
* missing means the number of patients missing the corresponding data, e.g., first row, 1 (sex) means 1 patient missing sex information. ** stages 0–2 are defined as early stage, while stages 3–4 are late stage.